Two Sigma Advisers’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-550,339
| Closed | -$6.16M | – | 2483 |
|
|
2017
Q3 | $6.16M | Buy |
550,339
+186,474
| +51% | +$2.06M | 0.02% | 723 |
|
|
2017
Q2 | $4M | Buy |
363,865
+160,204
| +79% | +$1.6M | 0.01% | 852 |
|
|
2017
Q1 | $2M | Buy |
203,661
+3,900
| +2% | +$39K | 0.01% | 1259 |
|
|
2016
Q4 | $2.16M | Sell |
199,761
-10,200
| -5% | -$102K | 0.01% | 1135 |
|
|
2016
Q3 | $2.15M | Buy |
209,961
+33,500
| +19% | +$365K | 0.01% | 995 |
|
|
2016
Q2 | $2.31M | Sell |
176,461
-10,100
| -5% | -$132K | 0.01% | 813 |
|
|
2016
Q1 | $2.05M | Sell |
186,561
-11,295
| -6% | -$100K | 0.01% | 799 |
|
|
2015
Q4 | $1.82M | Buy |
197,856
+6,495
| +3% | +$54.4K | 0.01% | 777 |
|
|
2015
Q3 | $1.34M | Sell |
191,361
-4,802
| -2% | -$41.1K | 0.01% | 879 |
|
|
2015
Q2 | $1.93M | Sell |
196,163
-5,398
| -3% | -$49.2K | 0.01% | 818 |
|
|
2015
Q1 | $1.79M | Buy |
201,561
+40,700
| +25% | +$324K | 0.01% | 825 |
|
|
2014
Q4 | $1.41M | Sell |
160,861
-50,500
| -24% | -$409K | 0.01% | 987 |
|
|
2014
Q3 | $1.46M | Buy |
211,361
+67,000
| +46% | +$401K | 0.01% | 943 |
|
|
2014
Q2 | $759K | Buy |
144,361
+800
| +0.6% | +$3.89K | 0.01% | 1361 |
|
|
2014
Q1 | $654K | Buy |
143,561
+1,800
| +1% | +$8.69K | 0.01% | 1404 |
|
|
2013
Q4 | $715K | Buy |
141,761
+12,400
| +10% | +$59.7K | 0.01% | 1353 |
|
|
2013
Q3 | $657K | Buy |
129,361
+6,100
| +5% | +$34K | 0.01% | 1218 |
|
|
2013
Q2 | $611K | Buy |
+123,261
| New | +$587K | 0.01% | 1195 |
|
Two Sigma Advisers's SCLN Position: Q4 2017 in Review
Two Sigma Advisers sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 550,339 shares — an estimated $6.16M sold.
Two Sigma Advisers first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $6.16M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Two Sigma Advisers reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Two Sigma Advisers sold 550,339 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $6.16M.
- Two Sigma Advisers first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Two Sigma Advisers's Sciclone Pharmaceuticals Inc position peaked at $6.16M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Two Sigma Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.